ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2011
Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis.Journal of Korean medical science · 2020Pooled it
- Pooled it
- Exercise effects on hip bone mineral density in older, post-menopausal breast cancer survivors are age dependent.Archives of osteoporosis · 2012Trial
- Differential Effects of Endocrine Therapy Type on Quality of Life in Older (≥70 Years) Women with Early-Stage Breast Cancer.Annals of surgical oncology · 2025Article
- Adjuvant radiotherapy for low-risk early breast cancer in elderly women: evidence from randomized trials.Translational cancer research · 2020Review
- Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy.Journal of cancer survivorship : research and practice · 2018Article
- Current Strategies of Endocrine Therapy in Elderly Patients with Breast Cancer.BioMed research international · 2018Review
- Management of bone health in postmenopausal women on aromatase inhibitors (AIs): a single health care system experience.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018Article
- Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.Journal of bone oncology · 2017Review
- Cost-effectiveness of dual-energy X-ray absorptiometry plus antiresorptive treatment in Australian women with breast cancer who receive aromatase inhibitors.Journal of bone and mineral metabolism · 2017Article
- Adjuvant systemic therapy in older women with breast cancer.Breast cancer (Dove Medical Press) · 2016Review
- Early-Stage Breast Cancer in the Elderly: Confronting an Old Clinical Problem.Journal of breast cancer · 2015Review
- Tamoxifen use reduces the risk of osteoporotic fractures in women with breast cancer in Asia: a nationwide population-based cohort study.BMC musculoskeletal disorders · 2015Article
- Minimal-trauma fracture in women with breast cancer surviving for at least 5 years from diagnosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Article
- Fracture risk and adjuvant therapies in young breast cancer patients: a population-based study.PloS one · 2015Article
- Femur fracture classification in women with a history of breast cancer.Journal of bone oncology · 2014Article
- Bone mineral density screening among women with a history of breast cancer treated with aromatase inhibitors.Journal of women's health (2002) · 2013Article
- Article
- Fracture risk in women with breast cancer: a population-based study.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
unlabelledThe risk of hip and other fractures was examined among a population-based group of older women with breast cancer. Women using aromatase inhibitors (AIs) were found to be over three times more likely to have a hip fracture over approximately 3 years' follow-up. Other fracture risk factors were also identified.
introductionAromatase inhibitors have been shown in randomized trials to increase total fracture risk compared with tamoxifen, but the fracture risks in the trials were relatively low, and no difference in hip fracture has been demonstrated.
methodsA population-based cohort of 2003 breast cancer survivors ≥65 were followed prospectively for a median of 36 months. Patient survey information regarding adjuvant breast cancer therapies, prescription osteoporosis treatments, and other factors potentially associated with fracture was supplemented with cancer registry information. Hip and total nonvertebral fractures were determined using a validated Medicare algorithm, and the association of these fractures with adjuvant hormonal therapies was examined using Cox models.
resultsThe cohort of 2,748 women with a mean age of 72.8 (SD 5.4) included 28.2% who took an aromatase inhibitor and 27.8% tamoxifen. There were 41 hip fractures (1.5%) and 218 nonvertebral fractures (7.9%) among the cohort. Subjects using AIs (adjusted hazard ratio 3.24 (1.05, 9.98)) and subjects not using hormone therapy (3.32 (1.14, 9.65)) were more likely than users of tamoxifen to have a hip fracture. Bisphosphonate use was more common among AI users but did not explain these results. Users of AIs were more likely to have nonvertebral fractures, but this result did not reach statistical significance (adjusted hazard 1.34 (0.92, 1.94)).
conclusionsHip and other fractures were common in an older population-based cohort of breast cancer survivors, and aromatase inhibitor use was associated with an increase in the short-term risk of hip fractures not detected in randomized controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.